

Article



# Extracorporeal Shock Wave Therapy (ESWT) vs. Exercise in Thumb Osteoarthritis (SWEX-TO): Prospective Clinical Trial at 6 Months

Ilaria Covelli <sup>1</sup>, Silvana De Giorgi <sup>1</sup>, Antonio Di Lorenzo <sup>2</sup>, Angelo Pavone <sup>1</sup>, Fabrizio Salvato <sup>1</sup>, Francesco Rifino <sup>1</sup>, Biagio Moretti <sup>1</sup>, Giuseppe Solarino <sup>1</sup> and Angela Notarnicola <sup>1,\*</sup>

- <sup>1</sup> Orthopedics Unit, Department of Translational Biomedicine and Neuroscience "DiBraiN", School of Medicine and Surgery, University of Bari, General Hospital, 70124 Bari, Italy; ilaria.covelli@uniba.it (I.C.); silvana.degiorgi@uniba.it (S.D.G.); a.pavone20@studenti.uniba.it (A.P.); f.salvato1@studenti.uniba.it (F.S.); francesco.rifino@policlinico.ba.it (F.R.); biagio.moretti@uniba.it (B.M.); giuseppe.solarino@uniba.it (G.S.)
- <sup>2</sup> Interdisciplinary Department of Medicine, University of Study of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy; antonio.dilorenzo@uniba.it
- \* Correspondence: angela.notarnicola@uniba.it; Tel.: +39-08055929238

**Abstract:** Rhizarthrosis is the most frequent form of osteoarthritis and is responsible for pain, disability and reduced functionality. The aim of the study is to investigate the clinical effects of shock wave treatment in patients suffering from arthritis of the first finger. A prospective clinical study was designed, in which 72 patients affected by rhizarthrosis were randomized to treatment with shock waves or exercises; in both groups an immobilization brace was used on the first finger. At recruitment and at 1, 3 and 6 months, patients received assessments of pain (VAS), functionality (FI-HOA) and disability (DASH); furthermore, the perception of improvement was monitored during follow-ups (Roles and Maudsley Score). In both groups there was a significant improvement in all scores in the comparison between recruitment and 6 months. The perception of improvement was statistically better in the shock wave group than in the exercise group at 1, 3 and 6 months. The regression analysis showed that the reduction of VAS and DASH were statistically influenced by shock wave treatment (*p* < 0.001). Both therapies are effective in managing patients suffering from arthritis of the first finger, but the shock wave treatment could ensure greater persistence of improvements.

**Keywords:** extracorporeal shock wave therapy; exercise; physical therapy; osteoarthritis; trapeziometacarpal; thumb

# 1. Introduction

Osteoarthritis (OA) is a degenerative inflammatory joint disease with high prevalence, negative effects on quality of life and high costs to the healthcare system [1].

It has been estimated that over 527 million people suffer from OA worldwide and the incidence of this disease is influenced by many factors, such as work, sports participation, musculoskeletal injuries, obesity and sex [2]. OA of the hands is the most common form and predominantly affects women. It occurs in 21% of the population over the age of 40 and causes pain and disability [3]. Furthermore, it is responsible for deformity, stiffness and reduced mobility and strength, limiting common activities such as opening containers, carrying objects and holding pens.

The treatment of choice for OA of the base of the first toe is conservative, while surgical treatment is reserved for those whose symptoms do not improve [3]. Surgical management, however, may be burdened by a number of complications, such as tendon rupture, sensory alterations and infection [4]. The traditional treatment involves a period of

Citation: Covelli, I.; De Giorgi, S.; Di Lorenzo, A.; Pavone, A.; Salvato, F.; Rifino, F.; Moretti, B.; Solarino, G.; Notarnicola, A. Extracorporeal Shock Wave Therapy (ESWT) vs. Exercise in Thumb Osteoarthritis (SWEX-TO): Prospective Clinical Trial at 6 Months. *Life* **2024**, *14*, 1453. https:// doi.org/10.3390/life14111453

## Academic Editor: Young-Ok Son

Received: 3 October 2024 Revised: 6 November 2024 Accepted: 7 November 2024 Published: 8 November 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). immobilization with a brace with a splint on the first finger, associated with physiotherapy treatment [5]. The use of the brace reduces pain, preserves first web space, stabilizes the base of the first metacarpal during pinching, and prevents adduction of the head of the first metacarpal into the palm of the hand and dorsal subluxation of the base of the metacarpal trapezius [6]. A program of specific exercises for the thenar muscles (traditionally pinching exercises) allows patients to rebalance the deforming force of the trapeziometacarpal joint, in which a strong traction by the adductor muscle of the thumb occurs, combined with the weakness of the intrinsic thenar muscles [5]. Physical therapy may improve pain and function in patients with OA of the base of the thumb [7]. The European League Against Rheumatism (EULAR) guidelines [8] recommend physical treatments, such as ultrasound, laser, analgesic currents and heat therapies. The first preliminary experiences relating to high-energy laser therapy have demonstrated effectiveness in reducing pain at 12 weeks [9]. As regards shock wave therapy, so far, only one work has advanced its potential for the treatment of rhizarthrosis [10].

The aim of this study is to compare the effects of a shock wave treatment compared to a standard treatment with exercises in patients suffering from arthritis of the first finger. Both treatments were associated with the use of a brace.

#### 2. Materials and Methods

The present study is a prospective randomized clinical trial to evaluate clinical and functional outcomes and satisfaction in patients affected by osteoarthritis of the first finger of the hand. The Territorial Ethics Committee of the "Consorziale Policlinico" University Hospital authorized the study (Interregional Ethics Committee, approval no. 7814, meeting of 20 December 2023). Participants gave their written informed consent. The trial was registered at https://clinicaltrials.gov/ with the trial registration number NCT06056765.

The patients were examined in the outpatient clinic of the Orthopedics and Traumatology Unit of the Policlinico di Bari, Italy. All eligible patients suffering from pain on the radial side of the carpus, which suggested arthrosis of the trapeziometacarpal joint, were examined by a hand surgeon. If the patient fell within the following stated criteria, they were selected for the study. The inclusion criteria were: trapeziometacarpal arthrosis with stage 1 or 2 of the Eaton–Littler radiographic classification and pain (recent radiograph within 6 months previously) [11]; clinical picture that has been occurring for at least 6 months; pain, counted with the Visual Analogue Scale (VAS), of at least 4/10. The exclusion criteria were: rheumatoid arthritis or results of trauma in the affected area; contraindications to treatment with Extracorporeal Shock Wave Treatment (ESWT) (neoplasia, pregnancy, thrombocytopenia, epilepsy, uncompensated heart disease or arrhythmia, pacemaker, local infections); corticosteroid infiltration or physical therapy in the previous 4 weeks. Seventy-two consecutive patients were recruited. Patients were randomized to two types of treatment: shock wave therapy (36 patients) (shock wave group) or therapeutic exercise (36 patients) (exercise group). All patients used a one-finger splint.

#### 2.1. Shock Wave Group

The therapy was applied using a focused shock wave device (Minilith, Storz, Schaffhausen, Switzerland) at the trapeziometacarpal joint, under ultrasound guidance (Figure 1). The shock wave therapy was performed with the patient's hand in intermediate pronosupination and was administered once a week for three sessions. For each treatment session, 2000 pulses were applied with an average energy flux density (EDF) between 0.03 and 0.08 mJ/mm<sup>2</sup> and a frequency of four pulses per second (4 Hz). Gel was used between the probe and the skin during applications to ensure conductivity. No local anesthetic was administered. The energy parameters and the delivery mode were defined in accordance with the literature [12].



**Figure 1.** Treatment of osteoarthritis of the trapeziometacarpal joint during shock wave therapy under ultrasound guidance. The positioning of the probe on the wrist during treatment (**a**) and ultrasound image of the district according to the long axis (TZ: trapezius; MC: first metacarpal), with the focal area of treatment identified (white cross) (**b**).

#### 2.2. Exercise Group Program

Patients were instructed in a stretching, stabilization and strengthening program for the thumbs in the 4 weeks following recruitment [13]. These exercises were aimed at stabilizing the muscles of the thumb, the first dorsal interosseous, the abductor pollicis and flexor pollicis brevis (FPB) muscles. The exercise was initially presented as active movement and, if tolerated, resistance was added. A single physiotherapist was involved for all patients in order to avoid operator bias. The same physiotherapist also provided instructions on the exercise program in the clinic and the subjects performed the exercise sessions at home, 2–3 times a day, every day. Each set of exercises took about 10 min. Once a week, a check-up was performed on the method and frequency of the exercises.

The exercises proposed were the following (Figure 2):

- 1. Massage the space between the first and second finger (thenar eminence) for 3 min (Figure 2a) [14,15].
- 2. Extend the space between first and second finger, maintaining for 30 s and perform four times per sitting (Figure 2b) [14].
- 3. "C" contraction: position the first finger and the remaining four fingers as if one wanted to form a "C"; maintain for 30 s and perform four times per sitting (Figure 2c) [14,15].
- 4. Active range of motion of the first dorsal interosseous: perform an active radial deviation of the index finger, with the hand resting on the table, for 10 repetitions [14–16]. If there was no pain, the next session of the exercise was performed with elastic resistance, asking to gradually increase the size and/or strength of the elastic band as much as possible. If there was pain, the previous movement was repeated (Figure 2d).
- 5. Active thumb abduction: active thumb abduction to maintain and/or increase the space between the first and second fingers, for 10 repetitions [14,15,17,18]. If the subject was able to complete 10 repetitions without pain, at the next session he was asked to perform this exercise with resistance (manually or through the use of an elastic band). The subject gradually increased the size and/or strength of the rubber band. If there was pain, he returned to the previous movement (Figure 2e).
- 6. Active flexion of the first finger: performing flexion of the trapeziometacarpal joint, for 10 repetitions [15,19]. If the subject was able to complete 10 repetitions with good technique, resistance was added manually or with rubber bands in the next session. If this exercise was painful, they were asked to return to active movement only (Figure 2f).



**Figure 2.** The six exercises administered to the exercise group. Exercise 1: Massaging the thenar eminence (**a**). Exercise 2: Extension of the space between the first and second finger (**b**). Exercise 3:

"C" contraction (c). Exercise 4: Active range of motion of the first dorsal interosseous (d). Exercise 5: Active thumb abduction (e). Exercise 6: Active flexion of the first finger (f).

#### 2.3. Post-Treatment Care

Patients in both groups were prescribed a full-time brace for 4 weeks to protect the joint and relieve inflammation and pain [20,21]. After this period, they were instructed regarding manual activities that should be avoided in order to prevent recurrence of pain in the trapeziometacarpal joint; these included the exclusion of a strong grip, an imbalance between joint movement and rest, exposure of the finger joints to vibration, and using the joint on an unstable plane [22].

#### 2.4. Outcome Measures

The assessments were conducted at the beginning of treatment (T0), at 1 month (T1), at 3 months (T2) and at 6 months (T3). At each time point, VAS, the Functional index for hand osteoarthritis (FIHOA), and Disabilities of the Arm, Shoulder and Hand (DASH) were administered. At T1, T2 and T3 the Roles and Maudsley Score was assessed.

- Pain was measured with the VAS scale, which consists of a 10 cm horizontal line (with 0 cm corresponding to no pain and 10 cm corresponding to worst pain ever experienced) [23].
- Hand functionality was studied with the Functional Index for Hand Osteoarthritis (FIHOA), which is a 10-item questionnaire, with four possible answers for each question (0 = possible without difficulty, 1 = possible slight with difficulty, 2 = possible with important difficulty, 3 = impossible); the score is between 0 (no limitation) and 30 (maximum limitation) [24].
- The disability is analyzed with the Disabilities of the Arm, Shoulder and Hand (DASH): 11 questions with five possible answers each (1 = No difficulty, 2 = Mild difficulty, 3 = Moderate difficulty, 4 = Severe difficulty, 5 = Unable) and a total score ranging from 11 (no difficulty) to 55 (inability) [25].
- The Roles and Maudsley Score evaluates the patient's perception of improvement, from 1 (excellent result with no symptoms following treatment) to 4 (poor, symptoms identical or worse than pre-treatment) [26].

#### 2.5. Statistical Analysis

Continuous variables will be presented as mean  $\pm$  standard deviation and range, while categorical variables will be expressed as proportions. To compare continuous variables between groups, either the independent *t*-test or the Wilcoxon rank-sum test will be utilized, depending on the data distribution. For the comparison of categorical variables between groups, the chi-square test will be employed. For all tests, a two-sided *p*-value < 0.05 was considered an indicator of statistical significance.

## 2.6. Sample Size

To estimate the sample size, we considered a VAS value of 7.5 at enrollment (T0) for both groups, with an average reduction at the primary endpoint (6 months) of 4.8 in the control group [13] and 3.8 in the treatment group [10], with a standard deviation of 1.4 for both groups. Sample size estimation was conducted using a t-test, with a significance level (alpha) set at 0.05 and a test power of 80%. The estimated sample size was 64 subjects, and to account for a potential 15% loss at follow-up, we aimed to recruit 72 subjects (36 per group). This effect was selected as the smallest effect that would be important to detect, meaning that a smaller effect would not have clinical or substantive significance.

The database was built via Microsoft Excel<sup>®</sup> 2019. The assignment to the groups was performed through randomization, ensuring homogeneity between the two groups for covariates such as sex and age. Due to the apparent nature of the two treatments, blinding

was not possible at a patient and physician level; assessors, however, were blind to the patients' randomization status.

Randomization was conducted using Stata MP17<sup>®</sup> software; the randomized patient list was generated in a pseudo-anonymous form, with a code linking each patient to their randomization ID in order to link each subject to their specific group and to their own record. All calculations were performed via Stata MP17<sup>®</sup> software.

#### 3. Results

### 3.1. Population Characteristics

The study enrolled 72 subjects, evenly distributed between the study group and control group (Figure 3).



#### CONSORT 2010 Flow Diagram

Figure 3. CONSORT flow diagram of participants throughout the study period.

The population's characteristics are stated in Tables 1 and 2. The mean age at diagnosis was 65.40 years ( $\pm$ 8.49 years), while the mean Body Mass Index (BMI) was 25.02 kg/m<sup>2</sup> ( $\pm$ 4.14 kg/m<sup>2</sup>). The mean time since the beginning of arthritic symptoms was 9.18 months ( $\pm$ 2.41 months).

Table 1. Study population characteristics: quantitative variables (mean ± standard deviation).

	Shock Wave Group	Exercise Group	Overall
Age (years)	$65.08 \pm 8.39$	$65.72 \pm 8.69$	$65.40 \pm 8.49$
BMI (kg/m <sup>2</sup> )	$25.59 \pm 3.28$	$24.45 \pm 3.28$	$25.05 \pm 4.14$
Time since onset (months)	$10 \pm 2.35$	$8.36 \pm 2.22$	$9.18 \pm 2.42$

		Shock Wave Group	Exercise Group	Overall
Sex	Female	18	18	36
	Male	18	18	36
Age	<65	18	18	36
	≧65	18	18	36
Dominant hand	Left	2	3	5
	Right	34	33	67
Arthrosis laterality	Left	13	6	19
	Right	23	30	53
Smoking habit	No	34	33	67
-	Yes	2	3	5
Hypertensive cardiopathy	No	26	27	53
	Yes	10	9	19
Metabolic/endocrine diseases	No	28	33	61
	Yes	8	3	9
Previous physiotherapy	No	26	29	55
	Yes	10	7	17
Radiological stage of disease	Stage 1	11	9	20
	Stage 2	25	27	52

Table 2. Study population characteristics: qualitative variables.

# 3.2. Endpoints

The VAS, FIHOA, DASH and Roles and Maudsley score values over time are described in Table 3. Normality was proven for the distribution of the VAS values over time. All other scores showed non-normal distribution in the study population. Therefore, the latter were studied via the Wilcoxon signed-rank test.

**Table 3.** Description of the main endpoints over time; the VAS score is described as median (interquartile range), while other endpoints are described as mean ± standard deviation.

	<b>T0</b>	T1	T2	T3
	VAS			
Shock wave group	7 (6–8)	4 (2–4.5)	3.5 (2–4)	2 (0–3)
Exercise group	6 (6–8)	4.5 (4–5)	2.5 (2-5)	4 (3–5)
Overall	7 (6–8)	4 (3–5)	3 (2–4)	3 (2-4.5)
	FIHOA			
Shock wave group	$13.64 \pm 6.39$	$7.89 \pm 5.10$	$7.06 \pm 5.18$	$6.56 \pm 5.28$
Exercise group	$12.64 \pm 4.04$	$8.00 \pm 2.97$	$6.81 \pm 2.71$	$7.36 \pm 3.10$
Overall	$13.14 \pm 5.33$	$7.94 \pm 4.14$	$6.93 \pm 4.11$	$6.96 \pm 4.32$
	DASH			
Shock wave group	$28.28 \pm 6.70$	$16.58 \pm 5.07$	$15.69 \pm 6.64$	$14.50 \pm 5.86$
Exercise group	$27.33 \pm 4.68$	$20.78 \pm 5.01$	$16.19\pm4.43$	$17.31 \pm 3.61$
Overall	$27.81 \pm 5.76$	$18.68 \pm 5.43$	$15.94 \pm 5.61$	$15.90 \pm 5.03$
	Roles and Maudsley			
Shock wave group		$1.94 \pm 0.71$	$1.75 \pm 0.73$	$1.53 \pm 0.77$
Exercise group		$2.58 \pm 0.55$	$2.33 \pm 0.63$	$2.42\pm0.73$
Overall		$2.26 \pm 0.71$	$2.04 \pm 0.74$	$1.97\pm0.87$

The mean VAS score showed a significant decrease from T0 to T3 in both the shock wave group (t: 12.80; *p*-value < 0.001) and the exercise group (t: 15.29; *p*-value < 0.001),

with a mean reduction of 4.81 ( $\pm 2.25$ ) in the shock wave group and 2.75 ( $\pm 1.08$ ) in the exercise group. When considering the intermediate checkpoints, both groups showed a significant reduction of the VAS score from T0 to T1 and from T1 to T2. For the shock wave group, in particular, the T0–T1 interval highlighted a mean 3.39 ( $\pm 1.76$ ) decrease (t: 11.55; *p*-value < 0.001) and the T1–T2 interval had a mean decrease of 0.72 ( $\pm 1.14$ ) (t: 3.81; *p*-value < 0.001). For the exercise group, the T0–T1 interval's VAS score reduction was 1.83 ( $\pm 0.74$ ) (t: 14.93; *p*-value < 0.001), while the T1–T2 interval had a mean 1.28 ( $\pm 1.00$ ) decrease (t: 7.64; *p*-value < 0.001). However, when the last interval was considered, a significant 0.69 ( $\pm 1.01$ ) decrease of the VAS score was highlighted in the shock wave group only (t: 4.13; *p*-value < 0.001), while the exercise group showed a slight, yet significant 0.36 ( $\pm 1.25$ ) increase of this score (t: -1.74; *p*-value: 0.045).

The FIHOA score showed a significant reduction over time in both groups. The decrease was 7.08 (±6.03) in the shock wave group (z: 5.12; *p*-value < 0.001) and 5.28 (±3.82) in the exercise group (z: 5.14; *p*-value < 0.001). Analyzing the single checkpoints, a consistently significant reduction was identified in the shock wave group for both the T0-T1 (mean:  $5.75 \pm 5.23$ ; *z*: 5.03; *p*-value < 0.001) and T1–T2 interval (mean:  $0.83 \pm 1.71$ ; *z*: 3.23; *p*-value: 0.001) and in the exercise group for the same intervals (T0-T1 mean: 4.64 ± 3.36; *z*: 5.22; *p*-value < 0.001; T1-T2 mean: 1.19 ±1.51; *z*: 4.32; *p*-value < 0.001). However, both groups showed no significant difference between the T2 and T3 values of the FIHOA score; the shock wave group, in particular, had a non-significant 0.56 (±2.21) increase (*z*: 1.90; *p*-value: 0.06), while the exercise group had a non-significant 0.56 (±2.21) increase (*z*: -1.42; *p*-value: 0.15).

A significant reduction of the DASH score was observed from T0 to T3. In the shock wave group, it was a 13.78 ( $\pm$ 7.52) decrease (z: 5.24; *p*-value < 0.001), while in the exercise group it was a 10.03 ( $\pm$ 4.35) decrease (z: 5.23; *p*-value < 0.001). When breaking the analysis down to the intermediate checkpoints, the study group showed a significant 11.69 ( $\pm$ 7.11) reduction of the DASH score from T0 to T1 (z: 5.23; *p*-value), the T1–T2 interval showed a significant 0.89 ( $\pm$ 3.97) decrease (z: 3.01; *p*-value < 0.01), and the T2–T3 interval highlighted a significant 1.19 ( $\pm$ 2.42) reduction (z: 3.40; *p*-value < 0.001). The exercise group, on the other hand, showed a significant 6.56 ( $\pm$ 3.42) decrease of the DASH score (z: 5.23; *p*-value < 0.001) from T0 to T1, followed by a still significant 4.58 ( $\pm$ 2.68) T1–T2 decrease (z: 5.15; *p*-value < 0.001); after the T2-T3 interval, however, a significant 1.11 ( $\pm$ 3.03) increase of the DASH score was observed (z: –2.07; *p*-value: 0.04).

## 3.3. Inferential Statistics

The VAS modification over time was significantly different between the shock wave and exercise groups (t: -4.94; *p*-value < 0.001). The DASH score reduction was also significantly different between the two groups (z: -2.70; *p*-value < 0.01). On the other hand, the FIHOA score changes did not significantly differ between the shock wave and exercise group (z: -0.98; *p*-value: 0.324). As far as the Roles and Maudsley score is concerned, the shock wave group showed a consistently lower score than the exercise one. The difference was significant at both T1 (z: 3.69; *p*-value < 0.001), T2 (z: 3.32; *p*-value < 0.001) and T3 (z: 4.48; *p*-value < 0.001).

#### 3.4. Regression Analysis

The VAS variation over time showed to be significantly impacted by the use of shock wave therapy, with a greater decrease in the shock wave group than in the exercise one (aOR: 2.14; 95% CI: 1.20–3.08; *p*-value < 0.001). The starting value of VAS was also directly associated with the score's reduction over time (aOR: 0.44; 95% CI: 0.07–0.81; *p*-value: 0.019). Both associations were confirmed by univariable regression (aOR for shock wave therapy: 2.06; 95% CI: 1.22–2.89; *p*-value < 0.001; aOR for VAS at T0: 0.66; 95% CI: 0.31–1.01; *p*-value < 0.001).

The reduction of the FIHOA score was not significantly impacted by the use of shock wave therapy (aOR: 1.93; 95% CI: -0.06-3.92; *p*-value: 0.057). However, a significant direct

association was shown for this score's value at T0 (aOR: 0.59; 95% CI: 0.40–0.78; *p*-value < 0.001), and a reverse association was highlighted for the Ray-X stage (aOR: -2.18; 95% CI: -4.29--0.07; *p*-value: 0.044). The impact of the T0 FIHOA score was further proved by the univariable regression (aOR: 0.63; 95% CI: 0.46–0.80; *p*-value < 0.001); the Ray-X stage, on the contrary, was not confirmed to be significant impactful on FIHOA score changes over time (aOR: -2.10; 95% CI: -4.75-0.54; *p*-value: 0.117).

The use of shock wave therapy showed a significant association with the DASH score decrease over time (aOR: 3.47; 95% CI: 0.98–5.96; *p*-value < 0.01). The DASH value at T0 was also significantly associated with the score's decrease (aOR: 0.74; 95% CI: 0.52–0.96; *p*-value < 0.001). Both results were confirmed by the univariable regression (aOR for shock wave therapy: 3.75; 95% CI: 0.86–6.64; *p*-value: 0.012; aOR for the DASH score at T0: 0.73; 95% CI: 0.53–0.93; *p*-value < 0.001).

Finally, the Roles and Maudsley score showed to be mainly influenced by the use of shock wave therapy. The shock wave group, in fact, showed a consistently lower Roles and Maudsley score at all checkpoints (aOR at T1: -0.69; 95% CI: -1.04--0.34; *p*-value < 0.001; aOR at T2: -0.66; 95% CI: -1.02--0.31; *p*-value < 0.001; aOR at T3: -1.01; 95% CI: -1.39--0.62; *p*-value < 0.001). Moreover, the score was significantly higher in subjects whose symptoms had started since a longer period of time both at T2 (aOR: 0.83; 95% CI: 0.01-0.16; *p*-value: 0.029) and T3 (aOR: 0.08; 95% CI: 0.01-0.16; *p*-value: 0.041). However, univariable regression did not confirm the impact of time since symptom onset on the Roles and Maudsley score (aOR at T2: 0.03; 95% CI: -0.04-0.10; *p*-value: 0.376; aOR at T3: 0.02; 95% CI: -0.07-0.10; *p*-value: 0.681). On the contrary, the reverse association of shock wave therapy with Roles and Maudsley score at T1 (aOR: -0.64; 95% CI: -0.94--0.34; *p*-value < 0.001), T2 (aOR: -0.58; 95% CI: -0.90--0.26; *p*-value: 0.001) and T3 (aOR: -0.89; 95% CI: -1.24--0.53; *p*-value < 0.001) was confirmed by univariable regression. The regression analyses results are summarized in Table 4.

ΔVAS				
Multivariable Regression				
Independent Variable	aOR	95% CI Lower Limit	95% CI Upper Limit	<i>p</i> -Value
Shock wave therapy *	2.14	1.20	3.08	< 0.001
VAS at T0 *	0.44	0.07	0.81	0.019
Sex (aOR for males vs. females)	0.37	-0.51	1.25	0.401
Age at diagnosis	0.02	-0.26	0.07	0.333
Right-hand dominance	-1.43	-3.25	0.38	0.119
BMI	-0.01	-0.12	0.12	0.968
Smoking habit	-0.14	-1.77	1.49	0.862
Affected hand				
(aOR for right hand vs.	0.44	-0.57	1.45	0.385
left hand)				
Months since symptoms' onset	-0.15	-0.35	0.04	0.114
Hypertensive cardiopa- thy	-0.22	-1.23	0.79	0.664
Endocrine diseases	0.43	-0.88	1.74	0.512
FANS therapy	0.21	-0.87	1.30	0.698
Previous physiotherapy	-0.14	-1.17	0.89	0.788
X-ray stage	-0.29	-1.30	0.73	0.571

**Table 4.** Summary of multivariable and univariable regression analyses results. Statistically significant associations are marked with an asterisk (\*).

Univariable Regression				
In daman dan t Maniah la	-OP	95% CI Lower	95% CI Upper	
Independent variable	aOK	Limit	Limit	<i>p</i> -value
Shock wave therapy *	2.06	1.22	2.89	< 0.001
VAS at T0 *	0.66	0.31	1.01	< 0.001
		ΔΓΙΗΟΑ		
	Multi	variable Regression		
Independent Variable	aOR	95% CI Lower	95% CI Upper	<i>p</i> -Value
	1.00	Limit	Limit	1
Shock wave therapy	1.93	-0.06	3.92	0.057
FIHOA at T0 *	0.59	0.40	0.78	< 0.001
Sex (aOR for males vs. females)	1.08	-0.85	3.01	0.266
Age at diagnosis	-0.3	-0.14	0.07	0.518
Right-hand dominance	-2.18	-6.07	1.71	0.265
BMI	-0.12	-0.36	0.13	0.333
Smoking habit	-2.73	-6.18	0.72	0.118
Affected hand				
(aOR for right hand vs. left hand)	1.34	-0.84	3.52	0.223
Months since symptoms' onset	-0.31	-0.72	0.10	0.133
Hypertensive cardiopa- thy	-0.77	-2.92	1.37	0.473
Endocrine diseases	0.65	-2.20	3.50	0.649
FANS therapy	0.35	-1.95	2.65	0.760
Previous physiotherapy	-0.54	-2.78	1.70	0.632
X-ray stage *	-2.18	-4.29	-0.07	0.044
	Univ	ariable Regression		
Indonandant Variabla	aOR	95% CI Lower	95% CI Upper	n-Valua
independent variable	aOK	Limit	Limit	<i>p</i> -value
Shock wave therapy *	0.63	0.46	0.80	< 0.001
X-ray stage	-2.10	-4.75	0.54	0.117
		ΔDASH		
	Multi	variable Regression		
Indonandant Variabla	2OR	95% CI Lower	95% CI Upper	n-Valua
independent variable	aOK	Limit	Limit	<i>p</i> -value
Shock wave therapy *	3.47	0.98	5.96	0.007
DASH at T0 *	0.74	0.52	0.96	< 0.001
Sex (aOR for males vs. females)	1.23	-1.28	3.74	0.331
Age at diagnosis	0.03	-0.10	0.17	0.633
Right-hand dominance	-1.14	-6.11	3.82	0.647
BMI	0.14	-0.17	0.46	0.360
Smoking habit Affected hand	-2.07	-6.47	2.33	0.350
(aOR for right hand vs. left hand)	1.09	-1.67	3.86	0.431
Months since symptoms' onset	-0.34	-0.87	0.18	0.200

Hypertensive cardiopa-	-2.07	-4.80	0.66	0.135
thy				
Endocrine diseases	1.71	-1.86	5.29	0.341
FANS therapy	0.26	-2.73	3.24	0.863
Previous physiotherapy	-0.94	-3.77	1.88	0.506
X-ray stage *	-1.35	-4.17	1.46	0.341
	Univa	ariable Regression		
Indonandant Variabla	2OR	95% CI Lower	95% CI Upper	n-Valuo
independent variable	aOK	Limit	Limit	<i>p</i> -value
Shock wave therapy *	3.75	0.86	6.64	0.012
DASH at T0 *	0.73	0.53	0.93	< 0.001
		R&M at T1		
	Multiv	variable Regression		
		95% CI Lower	95% CI Upper	
Independent Variable	aOR	Limit	Limit	<i>p</i> -Value
Shock wave therapy *	-0.69	-1.03	-0.34	<0.001
Shock wave inclupy Sex (aOR for males vs	0.07	1.00	0.01	40.001
fomalos)	0.10	-0.23	0.44	0.537
A go at diagnosis	0.01	-0.01	0.02	0.527
Pight hand dominance	0.01	-0.01	0.02	0.527
	0.20	-0.30	0.90	0.374
	-0.02	-0.92	0.32	0.279
Affected hand	-0.30	-0.92	0.32	0.332
(aOR for right hand vs. left hand)	-0.08	-0.47	0.30	0.671
Months since symptoms' onset	0.05	-0.02	0.13	0.131
Hypertensive cardiopa- thy	0.13	-0.25	0.52	0.491
Endocrine diseases	-0.43	-0.94	0.07	0.090
FANS therapy	-0.05	-0.46	0.36	0.813
Previous physiotherapy	0.15	-0.25	0.55	0.462
X-ray stage	-0.12	-0.49	0.26	0.530
	Univ	ariable Regression		
	• • • • •	95% CI Lower	95% CI Unner	
Independent Variable	aOR	Limit	Limit	<i>p</i> -Value
Shock wave therapy *	-0.64	-0.94	-0.34	<0.001
Shoek wave merupy	0.04	R&M at T2	0.04	<0.001
	Multi	Activitat 12		
	wiuiu		OF0/ CI Line or	
Independent Variable	aOR	95% CI Lower Limit	95% CI Upper Limit	<i>p</i> -Value
Shock wave therapy *	-0.66	-1.02	-0.31	< 0.001
Sex (aOR for males vs.	0.15	0.50	0.10	0.276
females)	-0.15	-0.50	0.19	0.376
Age at diagnosis	0.01	-0.01	0.03	0.318
Right-hand dominance	0.07	-0.65	0.78	0.854
BMI	-0.02	-0.06	0.03	0.415
Smoking habit	-0.15	-0.78	0.48	0.634
Affected hand	0.10	0.70	0.10	0.004
(aOR for right hand vs. left hand)	-0.01	-0.40	0.39	0.995

Months since symptoms' onset *	0.08	0.01	0.16	0.029
Hypertensive cardiopa- thy	-0.10	-0.49	0.30	0.620
Endocrine diseases	-0.31	-0.83	0.20	0.226
FANS therapy	-0.31	-0.74	0.11	0.142
Previous physiotherapy	0.26	-0.15	0.67	0.205
X-ray stage	-0.01	-0.39	0.37	0.956
	Univ	ariable Regression		
In Jones Jone Workship	-OP	95% CI Lower	95% CI Upper	u Value
Independent variable	aOK	Limit	Limit	<i>p</i> -value
Shock wave therapy *	-0.58	-0.90	-0.26	0.001
Months since symptoms' onset	0.32	-0.04	0.10	0.376
		R&M at T3		
	Multi	variable Regression		
Indonen dent Veriable	•OP	95% CI Lower	95% CI Upper	" Value
Independent variable	aOK	Limit	Limit	<i>p</i> -value
Shock wave therapy *	-1.01	-1.39	-0.62	< 0.001
Sex (aOR for males vs. females)	-0.06	-0.44	0.32	0.758
Age at diagnosis	-0.01	-0.02	0.02	0.877
Right-hand dominance	0.25	-0.54	1.03	0.531
BMI	-0.04	-0.09	0.01	0.078
Smoking habit Affected hand	-0.13	-0.82	0.56	0.716
(aOR for right hand vs. left hand)	-0.40	-0.83	0.03	0.067
Months since symptoms' onset*	0.08	0.01	0.16	0.041
Hypertensive cardiopa- thy	0.03	-0.40	0.46	0.898
Endocrine diseases	-0.45	-1.02	0.11	0.110
FANS therapy	-0.17	-0.63	0.29	0.458
Previous physiotherapy	0.12	-0.38	0.46	0.582
X-ray stage	0.04	-0.38	0.46	0.843
Univariable Regression				
Independent Variable	aOR	95% CI Lower	95% CI Upper	n-Value
	uON	Limit	Limit	r value
Shock wave therapy *	-0.89	-1.24	-0.53	< 0.001
Months since symptoms' onset	0.02	-0.07	0.10	0.681

## 4. Discussion

This study prospectively compared the benefits of conservative treatment with shock waves and bracing versus exercise and bracing, in patients with early stages of arthritis of the trapeziometacarpal joint (Eaton stages 1–2) [11]. In both groups there was a significant improvement in the assessed parameters of pain (VAS), function (FIHOA) and disability (DASH), in the comparison between recruitment and 6-month follow-up. In the two groups these improvements were also confirmed in the comparison between recruitment and 1 month and between 1 month and 3 months for all scores administered; regarding

the comparison between 3 and 6 months, the improvement was maintained only in the shock wave group for pain (VAS) and disability (DASH). In both groups the FIHOA did not present statistically significant improvements between 3 and 6 months. The Roles and Maudsley score presented statistically lower values in the shock wave group than in the exercise group at the three examination times.

In recent years, shock wave therapy has found application in many musculoskeletal pathologies [27]. Shock wave therapy is a physical therapy that exploits the biological effects of an acoustic wave that is focused in a small treatment area and causes cavitation effects [28]. This therapy has proven to be very effective in reducing pain and aiding the functional recovery of tendon pathologies, such as calcific cuff tendinopathy, tennis elbow syndrome, plantar fasciitis and tendon disease; it also allows the healing of fracture nonunions, bone edema and complex regional pain syndrome [28]. A recent meta-analysis demonstrated that the application of ESWT in patients suffering from knee osteoarthritis leads to statistically significant improvement in pain and functional recovery compared to other conservative therapy options [12]. The physical stimulus of shock waves determines an upregulation of various growth factors, modulation of inflammatory cytokines, chemotaxis of stem cells, proliferative effect and revascularizing action [29,30]. When shock waves are applied to the subchondral bone and articular cartilage, neovascularization, osteogenesis and chondrogenesis would occur [30-36]. On arthritic joints in an animal model, shock waves were able to determine motor recovery [37,38]. To date, only one clinical experience of the application of shock waves in the treatment of rhizarthrosis has been published [10]. Ioppolo and colleagues [10] conducted a clinical study in which they compared the effects of shock waves (SW) vs hyaluronic acid infiltration in the treatment of rhizarthrosis and the results were evaluated at the end of treatment and at 3 and 6 months. Pain reduction and functional recovery were found in both groups. In particular, as regards primary end points, pain, measured with the VAS scale, was significantly reduced by follow up in the two groups, with results in favor of shock waves at the end of treatment and at 6 months. As regards the Duruoz Hand Index functional scale, a functional recovery was recorded in both groups at the different FUs, without significant differences between the two treatments. As regards the secondary end points, in the shock wave group significant improvements were recorded in finger pinch strength at the end of the treatment and in hand grip strength at 6 months, without significant differences between the two groups The authors conclude that in the treatment of rhizarthrosis, ESWT could have superior effects to that of hyaluronic acid infiltration with regards to pain reduction, while it would appear to have similar effects with regards to functional and strength recovery. These results would be consistent with the analgesic and anti-inflammatory effects of ESWT and viscosupplementation of intra-articular HA injections.

In our experience the effect of shock waves has been compared with therapeutic exercise. Both therapies behave like mechanical stimuli, with biological effects on tissues. In particular, joint mobilization would determine beneficial effects both through biomechanical responses and neurophysiological effects [39,40]. In fact, movement determines the release of endorphins and substance P with inhibition of the nociceptive pathways. Therefore, the combined treatment of exercise and bracing provides good results in terms of clinical-functional recovery and stabilization of rhizarthrosis [14,16,41–43]. Studies demonstrate that the trapeziometacarpal joint receives its stability from the opposing thumb muscle, abductor pollicis, and the first interosseous [14,16,41–43].

Previous randomized clinical trials have shown that effective treatment must be continued for at least 2-4 weeks [43–45]. Pisano and colleagues [13] randomized 190 patients suffering from rhizarthrosis to a standard treatment or associated with home exercises and found clinical and functional improvement at 12 months, without statistically significant differences between the two groups. The results made it possible to confirm that the exercises allow the metacarpal trapezius joint to be stabilized, reducing pain and disability. On the other hand, increasing frequency with the addition of home exercises did not bring additional improvement. The strength of the study is that it is the first study to investigate shock wave treatment in patients suffering from rhizarthrosis in comparison with therapeutic exercise. This non-invasive therapeutic option has proven to be equivalent and could be a better alternative to exercise in patients with initial arthritis of the first finger, in particular with greater persistence of results at 6 months. Longer-term monitoring may allow us to verify the persistence of the benefits, as well as the opportunity to repeat a second cycle of shock waves and/or integration with other conservative treatments.

There are some limitations of the study that need to be considered. We did not use instrumental follow-up controls (X-ray, ultrasound, MRI), which could have provided an indication of the effects of the treatment on the cartilage, bone and muscle-tendon of the trapeziometacarpal joint. Furthermore, the brace may have been under-used or over-used by the patient. Furthermore, in relation to the type of treatment, the blinding of patients and professionals is lacking. There is no control group to distinguish whether the orthosis determines different effects compared to other therapies, considering that the prolonged use of an orthosis improves pain. We cannot eliminate the possibility that this could influence the results. We did not measure grip strength, hypothesizing that the variations in this parameter could be more relevant to the control group, which performed exercises. Another limitation of this study is that, despite periodic checks, we are not sure about the therapeutic adherence of the patients in the exercise group. Furthermore, there is no placebo group, and the number may be relatively low.

Finally, as a perspective for future sub-analysis, pain could be studied via categorization rather than numerical scales. In fact, categories may improve understanding of shockwave therapy on pain from a practical point of view. However, we chose to treat pain as a quantitative variable rather than a qualitative one for statistical purposes, in order to make it behave similarly to other endpoints and make the analysis more homogeneous.

## 5. Conclusions

In conclusion, this study offers a new treatment approach for rhizarthrosis in the early stage. Subsequent studies will be able to evaluate the effectiveness of a combined shock wave treatment, brace, and therapeutic exercise. The combined treatment could offer additional clinical benefits, improving tissue trophism and functional recovery, with longer duration of benefits. Longer-term monitoring will allow us to identify the persistence times of the benefits found.

**Author Contributions:** Conceptualization, A.N., I.C. and B.M.; methodology, A.N. and I.C.; formal analysis, A.D.L.; investigation, I.C.; data curation A.P., F.S. and F.R.; writing—original draft preparation, A.N.; writing—review and editing, A.N., S.D.G. and G.S.; supervision, G.S. and B.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Territorial Ethics Committee of the University Hospital Consortium of the Polyclinic of Bari (protocol code 7814, 20 December 2023). The study is registered at ClinicalTrials.gov (NCT06056765).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request due to privacy.

**Acknowledgments:** We gratefully acknowledge the colleagues and patients who enabled us to write this manuscript. We thank Donata Paolini for the adaptation of the photographic images.

Conflicts of Interest: The authors declare no conflicts of interest.

# References

- 1. Sharma, L. Osteoarthritis of the Knee. N. Engl. J. Med. 2021, 384, 51–59.
- Krakowski, P.; Rejniak, A.; Sobczyk, J.; Karpiński, R. Cartilage Integrity: A Review of Mechanical and Frictional Properties and Repair Approaches in Osteoarthritis. *Healthcare* 2024, 12, 1648.
- 3. Bridgforth, A.B.; Ross, P.R. Management of the Metacarpophalangeal and Scaphotrapeziotrapezoidal Joints in Patients with Thumb Trapeziometacarpal Arthrosis. *Hand Clin.* **2022**, *38*, 241–247.
- 4. Herren, D.B. Basal thumb arthritis surgery: Complications and its management. J. Hand Surg. Eur. Vol. 2024, 49, 188–200.
- 5. Normand, M.; Tang, T.S.; Brismée, J.M.; Sobczak, S. Clinical evaluation of thumb base osteoarthritis: A scoping review. *Hand Ther.* **2021**, *26*, 63–78.
- 6. Adams, J.; OTTER Trial Team. Comment on: The clinical and cost effectiveness of splints for basal thumb osteoarthritis: a randomized controlled trial. Reply. *Rheumatology* **2022**, *61*, e51.
- 7. Ahern, M.; Skyllas, J.; Wajon, A.; Hush, J. The effectiveness of physical therapies for patients with base of thumb osteoarthritis: Systematic review and meta-analysis. *Musculoskelet. Sci. Pract.* **2018**, *35*, 46–54.
- Kloppenburg, M.; Kroon, F.P.; Blanco, F.J.; Doherty, M.; Dziedzic, K.S.; Greibrokk, E.; Haugen, I.K.; Herrero-Beaumont, G.; Jonsson, H.; Kjeken, I.; et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. *Ann. Rheum. Dis.* 2019, *78*, 16–24.
- Cantero-Téllez, R.; Villafañe, J.H.; Valdes, K.; García-Orza, S.; Bishop, M.D.; Medina-Porqueres, I. Effects of High-Intensity Laser Therapy on Pain Sensitivity and Motor Performance in Patients with Thumb Carpometacarpal Joint Osteoarthritis: A Randomized Controlled Trial. *Pain Med.* 2020, 21, 2357–2365.
- Ioppolo, F.; Saracino, F.; Rizzo, R.S.; Monacelli, G.; Lanni, D.; Di Sante, L.; Cacchio, A.; Santilli, V.; Venditto, T. Comparison Between Extracorporeal Shock Wave Therapy and Intra-articular Hyaluronic Acid Injections in the Treatment of First Carpometacarpal Joint Osteoarthritis. *Ann. Rehabil. Med.* 2018, 42, 92–100.
- 11. Zarb, R.M.; Sasor, S.E. Physical Examination and Radiographic Staging of Thumb Carpometacarpal Arthritis. *Hand Clin.* **2022**, *38*, 141–148.
- 12. Chen, L.; Ye, L.; Liu, H.; Yang, P.; Yang, B. Extracorporeal Shock Wave Therapy for the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis. *BioMed Res. Int.* 2020, 2020, 1907821.
- 13. Pisano, K.; Wolfe, T.; Lubahn, J.; Cooney, T. Effect of a stabilization exercise program versus standard treatment for thumb carpometacarpal osteoarthritis: A randomized trial. *J. Hand Ther.* **2023**, *36*, 546–559.
- 14. O'Brien, V.H.; Giveans, M.R. Effects of a dynamic stability approach in conservative intervention of the carpometacarpal joint of the thumb: A retrospective study. *J. Hand Ther.* **2013**, *26*, 44–51, quiz 52.
- 15. Albrect, J. *Caring for the Painful Thumb: More Than a Splint;* Corporate Graphics: North Mankato, MN, USA, 2008.
- 16. Mobargha, N.; Esplugas, M.; Garcia-Elias, M.; Lluch, A.; Megerle, K.; Hagert, E. The effect of individual isometric muscle loading on the alignment of the base of the thumb metacarpal: A cadaveric study. *J. Hand Surg. Eur.* **2016**, *41*, 374–379.
- 17. Valdes, K.; von der Heyde, R. An exercise program for carpometacarpal osteoarthritis based on biomechanical principles. *J. Hand Ther.* **2012**, *25*, 251–262, quiz 263.
- 18. Pellegrini, V.D. Osteoarthritis at the base of the thumb. Orthop. Clin. N. Am. 1992, 23, 83–102.
- 19. Moulton, M.J.; Parentis, M.A.; Kelly, M.J.; Jacobs, C.; Naidu, S.H.; Pellegrini, V.D. Influence of metacarpophalangeal joint position on basal joint-loading in the thumb. *J. Bone Jt. Surg. Am.* **2001**, *83*, 709–716.
- 20. Efremova, L.; Igeta, Y.; Fabacher, T.; Hidalgo Diaz, J.J.; Gouzou, S.; Liverneaux, P.; Facca, S. Immbilization protocols following trapeziectomy for osteoarthritis of the thumb: 2 weeks versus 4 weeks. *Hand Surg. Rehabil.* **2022**, *41*, 73–77.
- Adams, J.; Barratt, P.; Rombach, I.; Arden, N.; Barbosa Bouças, S.; Bradley, S.; Doherty, M.; Dutton, S.J.; Gooberman-Hill, R.; Hislop-Lennie, K.; et al. The clinical and cost effectiveness of splints for thumb base osteoarthritis: A randomized controlled clinical trial. *Rheumatology* **2021**, *60*, 2862–2877.
- 22. Can, A.; Tezel, N. The effects of hand splinting in patients with early-stage thumb carpometacarpal joint osteoarthritis: A randomized, controlled study. *Turk. J. Med. Sci.* 2020, *50*, 1857–1864.
- 23. Shafshak, T.S.; Elnemr, R. The Visual Analogue Scale Versus Numerical Rating Scale in Measuring Pain Severity and Predicting Disability in Low Back Pain. J. Clin. Rheumatol. 2021, 27, 282–285.
- 24. Moraes, V.Y.; Faria, J.C.V.; Fernandes, M.; Raduan-Neto, J.; Okamura, A.; Belloti, J.C. Disability of Arm, Shoulder and Hand and Michigan Hand Outcomes Questionnaires: Exploring Responsiveness and Diagnostic Performance in a Sample of Outpatients with and without Hand and Wrist Complaints. *Rev. Bras. Ortop.* **2022**, *57*, 449–454.
- 25. Roles, N.C.; Maudsley, R.H. Radial tunnel syndrome: Resistant tennis elbow as a nerve entrapment. *J. Bone Jt. Surg. Br.* **1972**, *54*, 499–508.
- Notarnicola, A.; Moretti, B. The biological effects of extracorporeal shock wave therapy (eswt) on tendon tissue. *Muscles Ligaments Tendons J.* 2012, 2, 33–37.
- D Agostino, M.C.; Frairia, R.; Romeo, P.; Amelio, E.; Berta, L.; Bosco, V.; Gigliotti, S.; Guerra, C.; Messina, S.; Messuri, L.; et al. Extracorporeal shockwaves as regenerative therapy in orthopedic traumatology: A narrative review from basic research to clinical practice. *J. Biol. Regul. Homeost. Agents* 2016, *30*, 323–332.
- 28. Iannone, F.; Moretti, B.; Notarnicola, A.; Moretti, L.; Patella, S.; Patella, V.; Lapadula, G. Extracorporeal shock waves increase interleukin-10 expression by human osteoarthritic and healthy osteoblasts in vitro. *Clin. Exp. Rheumatol.* **2009**, *27*, 794–799.

- 29. Moretti, B.; Iannone, F.; Notarnicola, A.; Lapadula, G.; Moretti, L.; Patella, V.; Garofalo, R. Extracorporeal shock waves downregulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes. *BMC Musculoskelet*. *Disord.* **2008**, *31*, 16.
- Alshihri, A.; Niu, W.; Kämmerer, P.W.; Al-Askar, M.; Yamashita, A.; Kurisawa, M.; Spector, M. The effects of shock wave stimulation of mesenchymal stem cells on proliferation, migration, and differentiation in an injectable gelatin matrix for osteogenic regeneration. J. Tissue Eng. Regen. Med. 2020, 14, 1630–1640.
- 31. Simplicio, C.L.; Purita, J.; Murrell, W.; Santos, G.S.; Dos Santos, R.G.; Lana, J.F.S.D. Extracorporeal shock wave therapy mechanisms in musculoskeletal regenerative medicine. *J. Clin. Orthop. Trauma.* **2020**, *11* (Suppl. 3), S309–S318.
- Hsu, C.C.; Cheng, J.H.; Wang, C.J.; Ko, J.Y.; Hsu, S.L.; Hsu, T.C. Shockwave Therapy Combined with Autologous Adipose-Derived Mesenchymal Stem Cells Is Better than with Human Umbilical Cord Wharton's Jelly-Derived Mesenchymal Stem Cells on Knee Osteoarthritis. *Int. J. Mol. Sci.* 2020, *21*, 1217.
- Mostafa, M.S.E.M.; Hamada, H.A.; Kadry, A.M.; Zahran, S.S.; Helmy, N.A. Effect of High-Power Laser Therapy Versus Shock Wave Therapy on Pain and Function in Knee Osteoarthritis Patients: A Randomized Controlled Trial. *Photobiomodul. Photomed. Laser Surg.* 2022, 40, 198–204.
- 34. Notarnicola, A.; Iannone, F.; Maccagnano, G.; Lacarpia, N.; Bizzoca, D.; Moretti, B. Chondrocytes treated with different shock wave devices. *Muscles Ligaments Tendons J.* 2017, 7, 152–156.
- Tamma, R.; dell'Endice, S.; Notarnicola, A.; Moretti, L.; Patella, S.; Patella, V.; Zallone, A.; Moretti, B. Extracorporeal shock waves stimulate osteoblast activities. *Ultrasound Med. Biol.* 2009, *35*, 2093–2100.
- Dahlberg, J.; Fitch, G.; Evans, R.B.; McClure, S.R.; Conzemius, M. The evaluation of extracorporeal shockwave therapy in naturally occurring osteoarthritis of the stifle joint in dogs. *Vet. Comp. Orthop. Traumatol.* 2005, 18, 147–152.
- 37. Revenaugh, M.S. Extracorporeal shock wave therapy for treatment of osteoarthritis in the horse: Clinical applications. *Vet. Clin. N. Am. Equine Pract.* **2005**, *21*, 609–625.
- Bialosky, J.E.; Bishop, M.D.; Price, D.D.; Robinson, M.E.; George, S.Z. The mechanisms of manual therapy in the treatment of musculoskeletal pain: A comprehensive model. *Man. Ther.* 2009, 14, 531–538.
- 39. Bialosky, J.E.; George, S.Z.; Bishop, M.D. How spinal manipulative therapy works: Why ask why? *J. Orthop.* Sports *Phys. Ther.* **2008**, *38*, 293–295.
- 40. Vocelle, A.R.; Shafer, G.; Bush, T.R. Complex motions embedded in a hand exercise regimen—Effects on thumb function in participants with carpometacarpal osteoarthritis: A pilot study. *J. Clin. Transl. Sci.* **2023**, *7*, e234.
- 41. Norose, M.; Nimura, A.; Tsutsumi, M.; Fujita, K.; Okawa, A.; Akita, K. Anatomical study for elucidating the stabilization mechanism in the trapeziometacarpal joint. *Sci. Rep.* **2022**, *12*, 20790.
- 42. Colonna, S.; Borghi, C. Rhizarthrosis Part II: A New Approach of Manual Therapy and Therapeutic Exercise. *Cureus* **2024**, *16*, e52999.
- 43. Villafañe, J.H.; Silva, G.B.; Chiarotto, A. Effects of passive upper extremity joint mobilization on pain sensitivity and function in participants with secondary carpometacarpal osteoarthritis: A case series. J. Manip. Physiol. Ther. 2012, 35, 735–742.
- Villafañe, J.H.; Silva, G.B.; Diaz-Parreño, S.A.; Fernandez-Carnero, J. Hypoalgesic and motor effects of Kaltenborn mobilization on elderly patients with secondary thumb carpometacarpal osteoarthritis: A randomized controlled trial. *J. Manip. Physiol. Ther.* 2011, 34, 547–556.
- Villafañe, J.H.; Silva, G.B.; Fernandez-Carnero, J. Effect of thumb joint mobilization on pressure pain threshold in elderly patients with thumb carpometacarpal osteoarthritis. J. Manip. Physiol. Ther. 2012, 35, 110–120.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.